• Decoy Therapeutics highlighted its Designable Multi-Antivirals platform targeting viral fusion inhibition, aiming for one drug to cover multiple viruses.
• Presentation cited a structurally conserved target across 250+ human-infecting viruses, with programs designed to address 70%+ of annual virus-positive respiratory infections.
• Non-dilutive funding totaled $6.5 million, positioned as support from global health, technology, and government organizations.
• Company pointed to $5.7 billion in 2024 Paxlovid sales as evidence of a large, persistent antiviral market driven by mutation risk.
• Development plan emphasized two clinical programs in 24 months, enabled by an AI/ML design-build-test-learn workflow on Google Cloud.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.